SVCM
BCRX icon

Saturn V Capital Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Saturn V Capital Management’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-982,458
Closed -$6.96M – 24
2023
Q3 		$6.96M Buy
982,458
+27,602
+3% +$198K 2.91% 16
2023
Q2 		$6.72M Sell
954,856
-208,679
-18% -$1.67M 3.73% 14
2023
Q1 		$9.7M Buy
1,163,535
+823,372
+242% +$7.93M 7.25% 7
2022
Q4 		$3.75M Buy
+340,163
New +$4.24M 3.11% 16

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Saturn V Capital Management's BCRX Position: Q4 2023 in Review

Saturn V Capital Management sold out of BioCryst Pharmaceuticals (BCRX) in Q4 2023, closing a stake of 982,458 shares — an estimated $6.96M sold.

Saturn V Capital Management first reported a position in BCRX in Q4 2022 and held it in 4 quarters. The position peaked at $9.7M in Q1 2023. 235 funds tracked by Wall St. Rank hold BCRX as of Q4 2023.

  • Saturn V Capital Management reported no remaining BioCryst Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Saturn V Capital Management sold 982,458 BioCryst Pharmaceuticals shares in Q4 2023, an estimated $6.96M.
  • Saturn V Capital Management first reported a position in BioCryst Pharmaceuticals in Q4 2022 and held it in 4 quarters.
  • Saturn V Capital Management's BioCryst Pharmaceuticals position peaked at $9.7M in Q1 2023.
  • 235 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q4 2023.

Based on Saturn V Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.